Trials / Approved For Marketing
Approved For MarketingNCT02963350
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- —
Summary
* To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a clinical trial. * To collect additional information on the safety and tolerability of BMN 190 administration in patients with CLN2 disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1) |
Timeline
- First posted
- 2016-11-15
- Last updated
- 2017-07-24
Locations
5 sites across 4 countries: United States, Germany, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT02963350. Inclusion in this directory is not an endorsement.